Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 7867 · Infant Formula Safety Modernization Act of 2026 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 350a Infant formulas

+41 −1Shown
More for 21 U.S.C. § 350a
Read § 350aOnly this section
3 changes the bill asks for here, 3 carried out
  1. Carried out:

    Section 412(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 350a(b)) is amended by adding at the end the following:(5) (A) The Secretary shall by regulation update the good manufacturing practices for infant formulas established under this subsection to require the manufacturer of an infant formula to conduct pathogen and microorganism testing of— (i) the infant formula manufacturing …

  2. Carried out:

    Section 412 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 350a) is amended by adding at the end the following:(n) Congressional notification requirements.— (1) If the Secretary receives from a manufacturer a written notification of any test result that is a positive analytical result for a pathogen or microorganism in finished infant formula pursuant to subsection (b)(5)(B)(iii), the …

  3. Carried out:

    Section 412(b)(4)(A)(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 350a(b)(4)(A)(i)) is amended by striking paragraph (2)(B) and inserting paragraphs (2)(B) and (5)(A).

§ 350a(b)(4)(A)The Secretary shall by regulation establish requirements respecting the retention of records.…(i)–(iii)

Start of § 350a to (b)(4) unchanged ·

(A) The Secretary shall by regulation establish requirements respecting the retention of records. Such requirements shall provide for—

(i) the retention of all records necessary to demonstrate compliance with the good manufacturing practices and quality control procedures prescribed by the Secretary under paragraph (2), including records containing the results of all testing required under [struck: paragraph][inserted: paragraphs] (2)(B)[inserted: and (5)(A)],

(ii) the retention of all certifications or guarantees of analysis by premix suppliers,

(iii) the retention by a premix supplier of all records necessary to confirm the accuracy of all premix certifications and guarantees of analysis,

§ 350a(b)–(c)

(b)(4)(A)(iv)–(B) unchanged ·

(i) Records required under subparagraph (A) with respect to an infant formula shall be retained for at least one year after the expiration of the shelf life of such infant formula. Except as provided in clause (ii), such records shall be made available to the Secretary for review and duplication upon request of the Secretary.

(ii) A manufacturer need only provide written assurances to the Secretary that the regularly scheduled audits required by paragraph (2)(B)(iv) are being conducted by the manufacturer, and need not make available to the Secretary the actual written reports of such audits.

(5)

(A) [inserted: The Secretary shall by regulation update the good manufacturing practices for infant formulas established under this subsection to require the manufacturer of an infant formula to conduct pathogen and microorganism testing of—]

(i) [inserted: the infant formula manufacturing facilities of the manufacturer; and]

(ii) [inserted: in addition to other applicable testing requirements under this Act, the finished infant formula product of the manufacturer.]

(B) [inserted: The regulations issued under subparagraph (A) shall—]

(i) [inserted: require the Commissioner of Food and Drugs to develop a list of pathogens and microorganisms that infant formula manufacturers must test for in infant formula manufacturing facilities and finished infant formula products, which list shall include clostridium botulinum and such other pathogens and microorganisms as the Secretary designates;]

(ii) [inserted: specify the recommended frequency of environmental testing, including requirements for testing in Zones 2 and 3 of an infant formula manufacturing facility;]

(iii) [inserted: require the manufacturer of an infant formula to submit to the Secretary a written notification of any positive test result for a pathogen or microorganism referred to in clause (i) in infant formula, not later than one business day following the date of the result, even if the formula has not left the control of the manufacturer;]

(iv) [inserted: for the purposes of inspections conducted under this Act, require the manufacturer of an infant formula to retain records of any positive test result for a pathogen or microorganism referred to in clause (i)—]

(I) [inserted: in infant formula; or]

(II) [inserted: in the infant formula manufacturing facility of the manufacturer; and]

(v) [inserted: require Commissioner of Food and Drugs to establish and enforce clear, consistent inspection and compliance standards for all infant formula products, regardless of their country of origin.]

(C) [inserted: In this paragraph:]

(i) [inserted: The term “Zone 2”, with respect to an infant formula manufacturing facility, means areas directly adjacent to locations where infant formula could be exposed during manufacturing, but that are not food-contact surfaces.]

(ii) [inserted: The term “Zone 3”, with respect to an infant formula manufacturing facility, means areas further away from direct infant formula exposure than Zone 2, yet still within the processing environment; contamination in Zone 3 could reach Zone 2 (and thus the infant formula) through movement of people, equipment, or airflow.]

(c) Registration of persons distributing new infant formula

(1) No person shall introduce or deliver for introduction into interstate commerce any new infant formula unless—

§ 350a(m)–(n)

(c)(1)(A)–(m)(1)(B) unchanged ·

(2) Rule of construction Nothing in paragraph (1) shall be construed to limit the authority of the Secretary to require a recall of, or otherwise impose restrictions and requirements under this chapter with respect to, specialty infant formula that is subject to a waiver under paragraph (1).

(3) Definition of specialty infant formula In this subsection, the term “specialty infant formula” means infant formula described in subsection (h)(1).

(n) [inserted: Congressional notification requirements.—]

(1) [inserted: If the Secretary receives from a manufacturer a written notification of any test result that is a positive analytical result for a pathogen or microorganism in finished infant formula pursuant to subsection (b)(5)(B)(iii), the Secretary shall, not later than one business day following the date of such receipt, provide a written notice of such receipt to the appropriate committees of Congress.]

(2) [inserted: If the Food and Drug Administration issues an “official action indicated” classification (or an equivalent classification) following an inspection of an infant formula manufacturing facility, the Secretary shall, not later than one business day following the date of such issuance, provide a written notice of such issuance to the appropriate committees of Congress.]

(3) [inserted: In this subsection, the term “appropriate committees of Congress” means—]

(A) [inserted: the Committee on Appropriations and the Committee on Energy and Commerce of the House of Representatives; and]

(B) [inserted: the Committee on Appropriations and the Committee on Health, Education, Labor, and Pensions of the Senate.]

Step through the changes